

Jan Cornel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2876832/jan-cornel-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

251 papers	32,270 citations	65 h-index	179 g-index
284 ext. papers	39,165 ext. citations	10.8 avg, IF	6.5 L-index

#	Paper	IF	Citations
251	Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2.. <i>Circulation</i> , 2022 , 145, 626-628	16.7	1
250	IGF-1 is not related to long-term outcome in hyperglycemic acute coronary syndrome patients. <i>Diabetes and Vascular Disease Research</i> , 2021 , 18, 14791641211047436	3.3	0
249	Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021 , 16, e0260844	3.7	3
248	Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e71	6.4	1
247	Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal</i> , 2021 , 42, 2765-2775	9.5	31
246	Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTEMI-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. <i>European Heart Journal</i> , 2021 , 42, 2973-2985	9.5	10
245	Colchicine for secondary prevention in coronary disease. <i>European Heart Journal</i> , 2021 , 42, 1060-1061	9.5	1
244	Characteristics and prognostic value of right ventricular (dys)function in patients with non-ischaemic dilated cardiomyopathy assessed with cardiac magnetic resonance imaging. <i>ESC Heart Failure</i> , 2021 , 8, 1055-1063	3.7	4
243	The challenge of choosing in cardiovascular risk management. <i>Netherlands Heart Journal</i> , 2021 , 1	2.2	0
242	Targeting residual inflammatory risk in coronary disease: to catch a monkey by its tail. <i>Netherlands Heart Journal</i> , 2021 , 1	2.2	0
241	Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 859-866	15.1	4
240	Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. <i>American Journal of Medicine</i> , 2021 ,	2.4	3
239	Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy. <i>Atherosclerosis</i> , 2021 , 334, 93-100	3.1	3
238	Correlation between septal midwall late gadolinium enhancement on CMR and conduction delay on ECG in patients with nonischemic dilated cardiomyopathy. <i>IJC Heart and Vasculature</i> , 2020 , 26, 100474	2.4	0
237	Relation between pharmacological stress ECG, 13NH3-PET/CT outcome and the occurrence of cardiac events during follow-up in women with chest pain. <i>Nuclear Medicine Communications</i> , 2020 , 41, 783-789	1.6	
236	Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiratory distress syndrome in hospitalized patients with SARS-COV-2 Infection Disease. <i>American Heart Journal</i> , 2020 , 226, 60-68	4.9	9
235	Electronic health records to facilitate continuous detection of familial hypercholesterolemia. <i>Atherosclerosis</i> , 2020 , 310, 83-87	3.1	3

234	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 133-144	15.1	147
233	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. <i>Atherosclerosis</i> , 2020 , 293, 35-41	3.1	2
232	Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy. <i>Circulation</i> , 2020 , 142, 1996-1998	16.7	45
231	Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. <i>PLoS ONE</i> , 2020 , 15, e0237665	3.7	11
230	Colchicine in Patients with Chronic Coronary Disease. <i>New England Journal of Medicine</i> , 2020 , 383, 1838-1847	39.7	396
229	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019 , 394, 1169-1180	40	106
228	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. <i>New England Journal of Medicine</i> , 2019 , 381, 1309-1320	59.2	156
227	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1177-1186	15.1	33
226	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019 , 140, 1578-1589	16.7	24
225	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019 , 218, 57-65	4.9	3
224	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019 , 40, 2801-2809	9.5	27
223	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019 , 4, 680-684	16.2	7
222	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019 , 140, 103-112	16.7	72
221	Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. <i>Journal of the American Heart Association</i> , 2019 , 8, e011139	6	20
220	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. <i>Clinical Cardiology</i> , 2019 , 42, 498-505	3.3	19
219	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1167-1176	15.1	87
218	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2019 , 7, 618-628	18.1	120
217	Repeated Echocardiograms Do Not Provide Incremental Prognostic Value to Single Echocardiographic Assessment in Minimally Symptomatic Patients with Chronic Heart Failure: Results of the Bio-SHIFT Study. <i>Journal of the American Society of Echocardiography</i> , 2019 , 32, 1000-1009	5.8	2

216	The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2019 , 218, 46-56	4.9	30
215	PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers. <i>JACC: Cardiovascular Imaging</i> , 2019 , 12, 2571-2573	8.4	18
214	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005858	5.8	13
213	Longitudinally Measured Fibrinolysis Factors are Strong Predictors of Clinical Outcome in Patients with Chronic Heart Failure: The Bio-SHiFT Study. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1947-1955	7	7
212	Associations between β -blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. <i>American Heart Journal</i> , 2019 , 218, 92-99	4.9	1
211	Colchicine in Stable Coronary Artery Disease. <i>Clinical Therapeutics</i> , 2019 , 41, 30-40	3.5	20
210	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. <i>Circulation</i> , 2019 , 139, 1289-1299	16.7	223
209	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 489-496	15.1	41
208	Toward personalized risk assessment in patients with chronic heart failure: Detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study. <i>American Heart Journal</i> , 2018 , 196, 36-48	4.9	26
207	Exercise Electrocardiogram Neither Predicts Nor Excludes Coronary Artery Disease in Women with Low to Intermediate Risk. <i>Journal of Women's Health</i> , 2018 , 27, 476-484	3	2
206	The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy: A Review and Meta-Analysis. <i>JACC: Cardiovascular Imaging</i> , 2018 , 11, 1274-1284	8.4	109
205	Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study. <i>Kidney International</i> , 2018 , 93, 952-960	9.9	21
204	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet, The</i> , 2018 , 391, 319-328	40	430
203	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018 , 379, 2097-2107	59.2	1277
202	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018 , 392, 1519-1529	40	771
201	Inhibition of Interleukin-1 by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2405-2414	15.1	114
200	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. <i>American Heart Journal</i> , 2017 , 186, 91-99	4.9	24
199	Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT study. <i>International Journal of Cardiology</i> , 2017 , 235, 124-132	3.2	23

198	Early Invasive Versus Selective Strategy for Non-ST-Segment Elevation Acute Coronary Syndrome: The ICTUS Trial. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1883-1893	15.1	18
197	Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1587-1593	6.7	18
196	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). <i>Circulation</i> , 2017 , 136, 1193-1203	16.7	33
195	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017 , 63, 1214-1226	5.5	8
194	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. <i>Heart</i> , 2017 , 103, 1168-1176	5.1	25
193	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 376, 1713-1722	59.2	2700
192	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet, The</i> , 2017 , 389, 1799-1808	40	132
191	In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment. <i>Netherlands Heart Journal</i> , 2017 , 25, 634-642	2.2	6
190	Effect of interleukin-1 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2017 , 390, 1833-1842	40	634
189	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1119-1131	59.2	3877
188	Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 443-454	4.3	31
187	Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	2
186	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. <i>Diabetes Care</i> , 2016 , 39, 2304-2310	14.6	114
185	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 2373-2384	27.4	549
184	Independent prognostic value of coronary artery calcium score and coronary computed tomography angiography in an outpatient cohort of low to intermediate risk chest pain patients. <i>Netherlands Heart Journal</i> , 2016 , 24, 332-42	2.2	6
183	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGALE). <i>Diabetes Care</i> , 2016 , 39, 709-16	14.6	48
182	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. <i>Lancet, The</i> , 2016 , 387, 349-356	40	87
181	Discriminative Power of the HEART Score for Obstructive Coronary Artery Disease in Acute Chest Pain Patients Referred for CCTA. <i>Critical Pathways in Cardiology</i> , 2016 , 15, 6-10	1.3	2

180	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 126-35	16.2	161
179	Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2135-2144	15.1	46
178	Long-Term Follow-Up of the Randomized (BIOMArCS-2) Glucose Trial: Intensive Glucose Regulation in Hyperglycemic Acute Coronary Syndrome. <i>Circulation</i> , 2016 , 134, 984-6	16.7	2
177	Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes (TALISMAN) trial. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2057-2065	4.9	15
176	Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2015 , 115, 1325-32	3	16
175	High-pitch prospective ECG-triggered helical coronary computed tomography angiography in clinical practice: image quality and radiation dose. <i>International Journal of Cardiovascular Imaging</i> , 2015 , 31, 125-33	2.5	6
174	Ruling out coronary artery disease in women with atypical chest pain: results of calcium score combined with coronary computed tomography angiography and associated radiation exposure. <i>Journal of Women's Health</i> , 2015 , 24, 550-6	3	5
173	Anatomical versus Functional Testing for Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2015 , 373, 91	59.2	10
172	A multidisciplinary care pathway for the evaluation of falls and syncope in geriatric patients. <i>European Geriatric Medicine</i> , 2015 , 6, 487-494	3	8
171	Trends in incidence of infective endocarditis at the Medical Center of Alkmaar. <i>Netherlands Heart Journal</i> , 2015 , 23, 548-54	2.2	4
170	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015 , 169, 631-638.e7	4.9	72
169	Diagnostic and Therapeutic Usefulness of Coronary Computed Tomography Angiography in Out-Clinic Patients Referred for Chest Pain. <i>American Journal of Cardiology</i> , 2015 , 116, 30-6	3	4
168	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. <i>American Heart Journal</i> , 2015 , 169, 531-8	4.9	6
167	Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. <i>Circulation</i> , 2014 , 129, 2022-2032	16.7	79
166	Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. <i>American Heart Journal</i> , 2014 , 168, 76-87.e1	4.9	19
165	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2014 , 168, 68-75.e2	4.9	12
164	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. <i>European Heart Journal</i> , 2014 , 35, 2083-93	9.5	141
163	Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 883-91	7	21

162	Dehiscence of mitral valve annuloplasty: a three-dimensional diagnosis. <i>European Journal of Cardio-thoracic Surgery</i> , 2014 , 45, 393	3	
161	Coronary artery disease in patients with atypical chest pain with and without diabetes mellitus assessed with coronary CT angiography. <i>BMJ Open Diabetes Research and Care</i> , 2014 , 2, e000004	4.5	12
160	Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. <i>American Heart Journal</i> , 2014 , 168, 869-77.e1	4.9	17
159	Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. <i>EuroIntervention</i> , 2014 , 10, 431-8	3.1	22
158	Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATElet inhibition and patient outcomes (PLATO) trial. <i>American Heart Journal</i> , 2013 , 166, 474-80	4.9	27
157	Coronary artery pseudoaneurysm: closure with pericardium-covered stents, guided by cardiac computed tomography angiography. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1014.e11-2	3.8	2
156	Intensive glucose regulation does not reduce enzymatic infarct size in hyperglycemic acute coronary syndromes: results of the randomized BIOMArCS-2 glucose trial. <i>European Heart Journal</i> , 2013 , 34, P467-P467	9.5	
155	A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. <i>European Heart Journal</i> , 2013 , 34, 2481-9	9.5	70
154	Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial. <i>JAMA Internal Medicine</i> , 2013 , 173, 1896-904	11.5	32
153	Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1785-94	27.4	176
152	Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2012 , 366, 20-33	59.2	570
151	Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2012 , 164, 334-342.e1	4.9	47
150	Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 12-20	7	6
149	n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 309-18	59.2	659
148	Basal insulin and cardiovascular and other outcomes in dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 319-28	59.2	1138
147	Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. <i>New England Journal of Medicine</i> , 2012 , 367, 1297-309	59.2	631
146	Apixaban with antiplatelet therapy after acute coronary syndrome. <i>New England Journal of Medicine</i> , 2011 , 365, 699-708	59.2	765
145	Reply to Huang. <i>American Heart Journal</i> , 2011 , 161, e3	4.9	5

144	A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. <i>American Heart Journal</i> , 2011 , 161, 261-268.e1-2	4.9	29
143	N-terminal pro B-type natriuretic peptide identifies patients with chest pain at high long-term cardiovascular risk. <i>American Journal of Medicine</i> , 2011 , 124, 961-9	2.4	7
142	Intensive management of hyperglycaemia in acute coronary syndromes. Study design and rationale of the BIOMArCS 2 glucose trial. <i>Diabetic Medicine</i> , 2011 , 28, 1168-75	3.5	5
141	Long-term Clinical Outcome and MIBI SPECT Parameters in Percutaneous Coronary Interventions. <i>Netherlands Heart Journal</i> , 2011 , 19, 68-72	2.2	2
140	GRACE and TIMI risk scores but not stress imaging predict long-term cardiovascular follow-up in patients with chest pain after a rule-out protocol. <i>Netherlands Heart Journal</i> , 2011 , 19, 324-30	2.2	6
139	Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. <i>BMJ, The</i> , 2011 , 342, d3527	5.9	199
138	Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2011 , 32, 2933-44	9.5	262
137	Lenient versus strict rate control in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2010 , 362, 1363-73	59.2	623
136	Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2010 , 31, 3006-16	9.5	317
135	Elevated admission glucose is associated with increased long-term mortality in myocardial infarction patients, irrespective of the initially applied reperfusion strategy. <i>American Heart Journal</i> , 2010 , 160, 412-9	4.9	34
134	Precipitation and Transformation of the Three Polymorphs of d-Mannitol. <i>Industrial & Engineering Chemistry Research</i> , 2010 , 49, 5854-5862	3.9	48
133	Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. <i>Circulation</i> , 2010 , 122, 1056-67	16.7	280
132	The direct inverse method: a novel approach to estimate adsorption isotherm parameters. <i>Journal of Chromatography A</i> , 2010 , 1217, 1934-41	4.5	16
131	Experimental evidence of a delta-shock in nonlinear chromatography. <i>Journal of Chromatography A</i> , 2010 , 1217, 2002-12	4.5	41
130	Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. <i>Clinical Chemistry</i> , 2009 , 55, 1118-25	5.5	35
129	Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. <i>European Journal of Heart Failure</i> , 2009 , 11, 281-91	12.3	102
128	Infarct size in primary angioplasty without on-site cardiac surgical backup versus transferal to a tertiary center: a single photon emission computed tomography study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 237-43	8.8	1
127	Monitoring size and shape during cooling crystallization of ascorbic acid. <i>Chemical Engineering Science</i> , 2009 , 64, 163-171	4.4	16

126	One-year mortality after a first visit to a cardiology outpatient clinic: a useful performance indicator?. <i>Netherlands Heart Journal</i> , 2009 , 17, 52-5	2.2	2
125	Estimating Crystal Growth Rates Using in situ ATR-FTIR and Raman Spectroscopy in a Calibration-Free Manner. <i>Industrial & Engineering Chemistry Research</i> , 2009 , 48, 10740-10745	3.9	19
124	The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. <i>American Heart Journal</i> , 2009 , 158, 327-334.e4	4.9	111
123	Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1850-9	15.1	165
122	Experimental Characterization and Population Balance Modeling of the Polymorph Transformation of L-Glutamic Acid. <i>Crystal Growth and Design</i> , 2009 , 9, 243-252	3.5	74
121	Design and Optimization of a Combined Cooling/Antisolvent Crystallization Process. <i>Crystal Growth and Design</i> , 2009 , 9, 1124-1136	3.5	132
120	Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias. <i>European Heart Journal</i> , 2009 , 30, 645-54	9.5	27
119	Dutch Randomized Trial on Off-Site Primary PCI. <i>American Journal of Cardiology</i> , 2008 , 102, 1115	3	
118	Quantitative Application of in Situ ATR-FTIR and Raman Spectroscopy in Crystallization Processes. <i>Industrial & Engineering Chemistry Research</i> , 2008 , 47, 4870-4882	3.9	98
117	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008 , 372, 807-16	4.0	775
116	Calibration-free quantitative application of in situ Raman spectroscopy to a crystallization process. <i>Analytical Chemistry</i> , 2008 , 80, 9240-9	7.8	16
115	The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. <i>Cardiology</i> , 2008 , 110, 271-82	1.6	33
114	Percutaneous coronary intervention with off-site cardiac surgery backup for acute myocardial infarction as a strategy to reduce door-to-balloon time. <i>American Journal of Cardiology</i> , 2007 , 100, 1353-8	3	29
113	ST-segment deviation on the admission electrocardiogram, treatment strategy, and outcome in non-ST-elevation acute coronary syndromes A substudy of the Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) Trial. <i>Journal of Electrocardiology</i> , 2007 , 40, 408-15	1.4	10
112	Rosuvastatin in older patients with systolic heart failure. <i>New England Journal of Medicine</i> , 2007 , 357, 2248-61	59.2	1098
111	Inhibition of nonlinear acoustic cavitation dynamics in liquid CO ₂ . <i>Journal of Chemical Physics</i> , 2007 , 126, 064508	3.9	11
110	Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer-Alkmaar heart failure study. <i>Heart</i> , 2007 , 93, 819-25	5.1	96
109	N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. <i>American Heart Journal</i> , 2007 , 153, 485-92	4.9	32

108	The impact of admission plasma glucose on long-term mortality after STEMI and NSTEMI myocardial infarction. <i>International Journal of Cardiology</i> , 2007 , 121, 215-7	3.2	15
107	Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. <i>Lancet, The</i> , 2007 , 369, 827-835	4.0	106
106	Diagnostiek bij hartfalen 2007 , 71-93		
105	Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. <i>Circulation</i> , 2006 , 113, 671-8	16.7	694
104	Patient work in end-stage heart failure: a prospective longitudinal multiple case study. <i>Palliative Medicine</i> , 2006 , 20, 25-33	5.5	19
103	RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. <i>American Heart Journal</i> , 2006 , 152, 420-6	4.9	61
102	Safety and efficacy of a nurse-led clinic for post-operative coronary artery bypass grafting patients. <i>International Journal of Cardiology</i> , 2006 , 106, 111-5	3.2	18
101	Myocardial beta-adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo with PET using the new radioligand (S)-[11C]CGP12388. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005 , 32, 443-7	8.8	47
100	The value of haemostatic markers in the triage of patients with chest pain presenting with a normal or non-diagnostic ECG. <i>Heart</i> , 2005 , 91, 1215-6	5.1	1
99	Heart failure programmes in countries with a primary care-based health care system. Are additional trials necessary? Design of the DEAL-HF study. <i>European Journal of Heart Failure</i> , 2005 , 7, 910-20	12.3	23
98	Early invasive versus selectively invasive management for acute coronary syndromes. <i>New England Journal of Medicine</i> , 2005 , 353, 1095-104	59.2	384
97	A man with diabetes and heart failure. <i>Lancet, The</i> , 2004 , 364, 636	4.0	4
96	Endothelial dysfunction and reduced myocardial perfusion reserve in heart failure secondary to coronary artery disease. <i>American Journal of Cardiology</i> , 2003 , 91, 497-500	3	10
95	Prognostic value of predischage dobutamine stress echocardiography in chest pain patients with a negative cardiac troponin T. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 596-602	15.1	85
94	The prognostic value of markers of inflammation in patients with troponin T-negative chest pain before discharge from the emergency department. <i>American Journal of Medicine</i> , 2003 , 115, 521-8	2.4	16
93	Relaxivity Studies on Dinitroxide and Polynitroxyl Functionalized Dendrimers: Effect of Electron Exchange and Structure on Paramagnetic Relaxation Enhancement. <i>Journal of Physical Chemistry A</i> , 2003 , 107, 8467-8475	2.8	42
92	Sequential (201)Tl imaging and dobutamine echocardiography to enhance accuracy of predicting improved left ventricular ejection fraction after revascularization. <i>Journal of Nuclear Medicine</i> , 2002 , 43, 795-802	8.9	23
91	Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2001 , 12, 630-6	2.7	117

90	Time course of functional recovery of stunned and hibernating segments after surgical revascularization. <i>Circulation</i> , 2001 , 104, 1314-8	16.7	145
89	Impaired glucose metabolism predicts mortality after a myocardial infarction. <i>International Journal of Cardiology</i> , 2001 , 79, 207-14	3.2	174
88	Abnormal contractile responses during dobutamine stress echocardiography in patients with idiopathic dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2001 , 3, 429-36	12.3	13
87	Time Course of Functional Recovery of Stunned and Hibernating Segments After Surgical Revascularization. <i>Circulation</i> , 2001 , 104,	16.7	5
86	Relationship between preoperative viability and postoperative improvement in LVEF and heart failure symptoms. <i>Journal of Nuclear Medicine</i> , 2001 , 42, 79-86	8.9	52
85	Effect of coronary artery bypass surgery on myocardial perfusion and ejection fraction response to inotropic stimulation in patients without improvement in resting ejection fraction. <i>American Journal of Cardiology</i> , 2000 , 86, 490-4	3	6
84	Safety and prognostic value of early dobutamine-atropine stress echocardiography in patients with spontaneous chest pain and a non-diagnostic electrocardiogram. <i>European Heart Journal</i> , 2000 , 21, 397-406	8.5	67
83	Usefulness and limitations of dobutamine-atropine stress echocardiography for the diagnosis of coronary artery disease in patients with left bundle branch block. A multicentre study. <i>European Heart Journal</i> , 2000 , 21, 1666-73	9.5	61
82	Safety and efficacy of treatment with platelet GPIIb/IIIa receptor blockade in unstable angina patients awaiting PTCA at a referring clinic. <i>International Journal of Cardiovascular Interventions</i> , 1999 , 2, 223-230		
81	Delayed recovery of hibernating myocardium after surgical revascularization: implications for discrepancy between metabolic imaging and dobutamine echocardiography for assessment of myocardial viability. <i>Journal of Nuclear Cardiology</i> , 1999 , 6, 685-7	2.1	12
80	Agreement and disagreement between "metabolic viability" and "contractile reserve" in akinetic myocardium. <i>Journal of Nuclear Cardiology</i> , 1999 , 6, 383-8	2.1	26
79	Dobutamine stress thallium-201 single-photon emission tomography versus echocardiography for evaluation of the extent and location of coronary artery disease late after myocardial infarction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999 , 26, 467-73	8.8	4
78	Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). <i>Lancet, The</i> , 1999 , 353, 2001-2007	40	3766
77	Echocardiographic studies of dobutamine-induced ST-segment elevation before and after coronary artery bypass grafting in patients with old Q-wave myocardial infarction. <i>Journal of the American Society of Echocardiography</i> , 1999 , 12, 48-54	5.8	4
76	Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 163-9	15.1	266
75	Relation between Viability, Improvement of Lvef and Heart Failure Symptoms after Revascularization 1999 , 223-227		
74	Prediction of improvement of regional left ventricular function after revascularization using different perfusion-metabolism criteria. <i>Journal of Nuclear Medicine</i> , 1999 , 40, 1866-73	8.9	14
73	Dobutamine-atropine stress myocardial perfusion SPECT imaging in the diagnosis of graft stenosis after coronary artery bypass grafting. <i>Journal of Nuclear Cardiology</i> , 1998 , 5, 491-7	2.1	14

72	Biphasic response to dobutamine predicts improvement of global left ventricular function after surgical revascularization in patients with stable coronary artery disease: implications of time course of recovery on diagnostic accuracy. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 1002-10	15.1	136
71	Prognostic implications of a normal dobutamine-atropine stress echocardiogram in patients with chest pain. <i>Journal of the American Society of Echocardiography</i> , 1998 , 11, 606-11	5.8	8
70	Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction. <i>European Heart Journal</i> , 1998 , 19, 1712-8	9.5	34
69	FDG SPECT to Assess Myocardial Viability. <i>Developments in Cardiovascular Medicine</i> , 1998 , 249-260		
68	Assessment of myocardial viability by FDG imaging with SPECT. <i>Developments in Cardiovascular Medicine</i> , 1998 , 299-309		
67	Comparison of fluorine-18-FDG with rest-redistribution thallium-201 SPECT to delineate viable myocardium and predict functional recovery after revascularization. <i>Journal of Nuclear Medicine</i> , 1998 , 39, 1481-6	8.9	20
66	Digoxin in patients with heart failure. <i>New England Journal of Medicine</i> , 1997 , 337, 129; author reply 130-1	5.2	4
65	Relation between ST segment elevation during dobutamine stress test and myocardial viability after a recent myocardial infarction. <i>Heart</i> , 1997 , 77, 115-21	5.1	15
64	FDG SPECT in the assessment of myocardial viability. Comparison with dobutamine echo. <i>European Heart Journal</i> , 1997 , 18 Suppl D, D124-9	9.5	7
63	Prediction of improvement of ventricular function after revascularization. 18F-fluorodeoxyglucose single-photon emission computed tomography vs low-dose dobutamine echocardiography. <i>European Heart Journal</i> , 1997 , 18, 941-8	9.5	17
62	Cardiac 18F-FDG-SPET studies in patients with non-insulin-dependent diabetes mellitus during hyperinsulinaemic euglycaemic clamping. <i>Nuclear Medicine Communications</i> , 1997 , 18, 200-6	1.6	10
61	Comparison between 360 degrees and 180 degrees data sampling in thallium-201 rest-redistribution single-photon emission tomography to predict functional recovery after revascularization. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997 , 24, 516-22		12
60	Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997 , 24, 35-41		61
59	Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. <i>Lancet, The</i> , 1997 , 349, 1429-1435	40	996
58	Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography. <i>Journal of the American College of Cardiology</i> , 1997 , 30, 377-83	15.1	69
57	Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. <i>Journal of the American College of Cardiology</i> , 1997 , 30, 1451-60	15.1	417
56	Impact of severity of coronary artery stenosis and the collateral circulation on the functional outcome of dyssynergic myocardium after revascularization in patients with healed myocardial infarction and chronic left ventricular dysfunction. <i>American Journal of Cardiology</i> , 1997 , 79, 883-8	3	25
55	Predictive accuracy of echocardiographic response of mildly dyssynergic myocardial segments to low-dose dobutamine. <i>American Journal of Cardiology</i> , 1997 , 80, 1481-4	3	12

54	Dobutamine stress-redistribution-reinjection versus rest-redistribution thallium-201 SPECT in the assessment of myocardial viability. <i>International Journal of Cardiovascular Imaging</i> , 1997 , 13, 59-64		2
53	Metabolic imaging using F18-fluorodeoxyglucose to assess myocardial viability. <i>International Journal of Cardiovascular Imaging</i> , 1997 , 13, 145-55; discussion 157-60		20
52	Improved detection of viable myocardium with fluorodeoxyglucose-labeled single-photon emission computed tomography in a patient with hibernating myocardium: comparison with rest-redistribution thallium 201-labeled single-photon emission computed tomography. <i>Journal of Nuclear Cardiology</i> , 1997 , 4, 178-9	2.1	4
51	F18-fluorodeoxyglucose single-photon emission computed tomography predicts functional outcome of dyssynergic myocardium after surgical revascularization. <i>Journal of Nuclear Cardiology</i> , 1997 , 4, 302-8	2.1	19
50	Cardiac imaging for risk stratification with dobutamine-atropine stress testing in patients with chest pain. Echocardiography, perfusion scintigraphy, or both?. <i>Circulation</i> , 1997 , 96, 137-47	16.7	72
49	Hemodynamic changes, plasma catecholamine responses, and echocardiographically detected contractile reserve during two different dobutamine-infusion protocols. <i>Journal of Cardiovascular Pharmacology</i> , 1997 , 29, 808-13	3.1	3
48	Prediction of Improvement in Global and Regional Ventricular Function after Revascularization with FDG SPECT 1997 , 173-178		
47	Regional Perfusion and Metabolism before Revascularization Compared with Functional Outcome 1997 , 447-450		
46	Assessment of myocardial viability by dobutamine stress echocardiography. <i>Current Opinion in Cardiology</i> , 1996 , 11, 621-6	2.1	18
45	Coronary-artery bypass surgery with internal-thoracic-artery grafts. <i>New England Journal of Medicine</i> , 1996 , 334, 1609; author reply 1610	59.2	1
44	Safety and feasibility of dobutamine-atropine stress echocardiography in patients with ischemic left ventricular dysfunction. <i>Journal of the American Society of Echocardiography</i> , 1996 , 9, 27-32	5.8	35
43	Comparison of thallium-201 rest-redistribution SPECT and FDG SPECT in predicting functional recovery after revascularization. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 300-301	15.1	2
42	Dobutamine-induced hypoperfusion without transient wall motion abnormalities: less severe ischemia or less severe stress?. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 323-9	15.1	44
41	Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 447-54	15.1	35
40	Prediction of recovery of myocardial dysfunction after revascularization. Comparison of fluorine-18 fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 558-64	15.1	179
39	Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction. <i>American Heart Journal</i> , 1996 , 131, 1088-96	4.9	27
38	Altered myocardial perfusion during dobutamine stress testing in silent versus symptomatic myocardial ischaemia assessed by quantitative MIBI SPET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996 , 23, 1354-60		5
37	Comprehensive analysis of aortic valve vegetation with anyplane, paraplane, and three-dimensional echocardiography. <i>European Heart Journal</i> , 1996 , 17, 318-20	9.5	9

36	Prediction of reversibility of wall motion abnormalities after revascularization using F18-fluorodeoxyglucose single photon emission computed tomography. <i>European Heart Journal</i> , 1996 , 17, 480-1	9.5	2
35	T wave normalization during dobutamine stress testing in patients with non-Q wave myocardial infarction. A marker of myocardial ischaemia?. <i>European Heart Journal</i> , 1996 , 17, 526-31	9.5	16
34	Akinesis becoming dyskinesis during dobutamine stress echocardiography. A predictor of poor functional recovery after surgical revascularization. <i>Chest</i> , 1996 , 110, 155-8	5.3	23
33	Relation between contractile response of akinetic segments during dobutamine stress echocardiography and myocardial ischemia assessed by simultaneous thallium-201 single-photon emission computed tomography. <i>American Journal of Cardiology</i> , 1996 , 77, 955-9	3	45
32	Prognostic significance of normal dobutamine-atropine stress sestamibi scintigraphy in women with chest pain. <i>American Journal of Cardiology</i> , 1996 , 77, 1057-61	3	33
31	Assessment of patients after coronary artery bypass grafting by dobutamine stress echocardiography. <i>American Journal of Cardiology</i> , 1996 , 77, 1234-6	3	16
30	Accuracy of dobutamine stress echocardiography for the diagnosis of coronary artery stenosis in patients with myocardial infarction: the impact of extent and severity of left ventricular dysfunction. <i>Heart</i> , 1996 , 76, 123-8	5.1	24
29	Prognostic Value of Dobutamine-Atropine Stress Technetium-99m Sestamibi Perfusion Scintigraphy in Patients With Chest Pain. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 447-454	15.1	48
28	Prediction of Recovery of Myocardial Dysfunction After Revascularization Comparison of Fluorine-18 Fluorodeoxyglucose/Thallium-201 SPECT, Thallium-201 Stress Re-injection SPECT and Dobutamine Echocardiography. <i>Journal of the American College of Cardiology</i> , 1996 , 28, 558-564	15.1	9
27	Dobutamine thallium-201 SPECT imaging for assessment of peri-infarction and remote myocardial ischemia. <i>Journal of Nuclear Medicine</i> , 1996 , 37, 1951-6	8.9	11
26	Correlation of coronary stenosis by quantitative coronary arteriography with exercise echocardiography. <i>American Journal of Cardiology</i> , 1995 , 75, 287-90	3	14
25	Quantitative angiographic measurements of isolated left anterior descending coronary artery stenosis. Correlation with exercise echocardiography and technetium-99m 2-methoxy isobutyl isonitrile single-photon emission computed tomography. <i>Journal of the American College of Cardiology</i> , 1995 , 25, 1161-7	15.1	19
24	Improved identification of coronary artery disease in patients with left bundle branch block by use of dobutamine stress echocardiography and comparison with myocardial perfusion tomography. <i>American Journal of Cardiology</i> , 1995 , 76, 321-5	3	59
23	Evaluation by quantitative 99m-technetium MIBI SPECT and echocardiography of myocardial perfusion and wall motion abnormalities in patients with dobutamine-induced ST-segment elevation. <i>American Journal of Cardiology</i> , 1995 , 76, 441-8	3	44
22	T-wave normalization during dobutamine echocardiography for diagnosis of viable myocardium. <i>American Journal of Cardiology</i> , 1995 , 75, 505-7	3	23
21	Stress-induced left ventricular dysfunction in silent and symptomatic myocardial ischemia during dobutamine stress test. <i>American Journal of Cardiology</i> , 1995 , 75, 1112-5	3	10
20	Prediction of improvement of regional left ventricular function after surgical revascularization. A comparison of low-dose dobutamine echocardiography with 201Tl single-photon emission computed tomography. <i>Circulation</i> , 1995 , 91, 2748-52	16.7	229
19	Assessment of Myocardial Viability by Pharmacological Stress Echocardiography. <i>Developments in Cardiovascular Medicine</i> , 1995 , 103-115		

18	Dobutamine-atropine stress echocardiography in elderly patients unable to perform an exercise test. Hemodynamic characteristics, safety, and prognostic value. <i>Archives of Internal Medicine</i> , 1994 , 154, 2681-6		41
17	Prediction of improvement of ventricular function after first acute myocardial infarction using low-dose dobutamine stress echocardiography. <i>American Journal of Cardiology</i> , 1994 , 74, 853-6	3	65
16	Safety of dobutamine-atropine stress echocardiography in patients with suspected or proven coronary artery disease. <i>American Journal of Cardiology</i> , 1994 , 73, 456-9	3	123
15	Akinesis becoming dyskinesia during high-dose dobutamine stress echocardiography: a marker of myocardial ischemia or a mechanical phenomenon?. <i>American Journal of Cardiology</i> , 1994 , 73, 896-9	3	129
14	Dobutamine-atropine stress echocardiography and clinical data for predicting late cardiac events in patients with suspected coronary artery disease. <i>American Journal of Medicine</i> , 1994 , 97, 119-25	2.4	73
13	Potential and limitations of Tc-99m sestamibi scintigraphy for the diagnosis of myocardial viability. <i>Herz</i> , 1994 , 19, 19-27	2.6	6
12	Intracoronary albuterol. Its effects on left ventricular hemodynamics, function, and coronary sinus flow in humans. <i>Circulation</i> , 1993 , 88, 2123-7	16.7	35
11	Preliminary clinical experience with intracoronary Albuterol: a standardized echocontrast agent. <i>Developments in Cardiovascular Medicine</i> , 1993 , 109-120		
10	Exercise echocardiography versus thallium-201 SPECT for assessing patients before and after PTCA. <i>European Heart Journal</i> , 1992 , 13, 213-9	9.5	45
9	Myocardial contrast echocardiography can depict thebesian vein outflow in humans. <i>American Heart Journal</i> , 1992 , 123, 1373-4	4.9	2
8	Relationship between exercise echocardiography and perfusion single-photon emission computed tomography in patients with single-vessel coronary artery disease. <i>American Heart Journal</i> , 1992 , 124, 75-83	4.9	50
7	Clinical experience with Albuterol: a standard echocontrast agent for intravenous and intracoronary use. <i>American Journal of Cardiac Imaging</i> , 1991 , 5, 217-23		5
6	Myocardial contrast echocardiography during hyperemia. <i>Coronary Artery Disease</i> , 1990 , 1, 573-578	1.4	3
5	The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man. <i>Chest</i> , 1990 , 98, 1440-4	4.3	17
4	Evaluation of collateral blood flow by myocardial contrast enhanced echocardiography. <i>Heart</i> , 1988 , 59, 20-2	5.1	22
3	Detection of left coronary artery stenosis by transoesophageal echocardiography. <i>European Heart Journal</i> , 1988 , 9, 1162-6	9.5	39
2	Effect of papaverine administration on myocardial echocontrast distribution. <i>American Heart Journal</i> , 1987 , 114, 1248-9	4.9	9
1	Quantitative assessment of myocardial blood flow by contrast two-dimensional echocardiography: initial clinical observations. <i>American Journal of Physiologic Imaging</i> , 1987 , 2, 56-60		7

